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two focus groups with a total of 14 patients, six individual inter-
views with accompanying relatives and 14 individual interviews 
with HCPs were conducted. Stigmatization was reported in all 
surveyed subgroups. In particular, self-stigmatization among 
those affected and their relatives was evident and perceived 
as a limitation within social and professional environments. 
Discussion: Through meetings between affected and unaffected 
persons, which can act as possible multipliers, it is hoped that 
both the public and self-stigmatization experienced by sufferers 
of psoriasis can be reduced. 
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Introduction: Hidradenitis Suppurativa (HS) has been associated 
with impaired quality of life (QoL). There are various measuring 
systems to assess physical severity; however, there are no speci-
fic QoL questionnaires for this disease in the Spanish language. 
Objective: To develop and validate a disease-specific instrument 
to measure QoL in patients with HS. Methods: A literature search 
was carried out to prepare a semi structured interview for patients 
with HS, as well as a Delphi expert consensus among health profes-
sionals. The validation with a sample of 130 patients is presented. 
The preliminary validation of the HSQoL-24 was passed twice to 
a group of 30 patients with 30 ± 10 days of interval. The DLQI and 
the Skindex-29 were used for its validation. Results: Cronbach 
alpha 0.87 indicates a good internal consistency of the questionn-
aire. The intraclass correlation coefficient (ICC) with the DLQI 
was 0.70 (p-value) (< 0.001), and 0.87 (p-value) (< 0.001) with 
the Skindex-29. Conclusions: The HSQoL-24 is the first specific 
self-administered questionnaire to assess QoL in patients with HS 
in Spanish. It is user friendly and easy to. This study demonstra-
tes the excellent properties of the instrument: comprehensibility, 
reliability (test-retest), internal consistency, validity, comparison 
with DLQI and SKINDEX-29, and discriminative capacity. 
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Background: Dupilumab, an anti-interleikin-4-receptor-α mo-
noclonal antibody, is a new treatment for atopic dermatitis in 
adults. Objective: To evaluate – at week 52 – patient reported 
outcomes, satisfaction, efficacy and safety, with dupilumab 
in adult patients with moderate-to-severe atopic dermatitis 
refractory to the usual treatments previously performed under 
conditions of usual clinical practice. Methods: Twelve patients 
were enrolled. Patients from our hospital, under routine clinical 
practice, were treated with subcutaneous dupilumab 300 mg 
every 2 weeks. The outcomes were evaluated at baseline, week 
4, 8, 12, 16, 28 ,40 and week 52. The variables evaluated were: 
itch, difficulty to sleep, previous stressful life events, severity 
(SCORAD), anxiety and depression symptoms (HADS), quality 
of life (DLQI, EQ5D3L), satisfaction, adherence to the treatment, 
efficacy and safety. Results: At week 52 significant improvement 
was observed in severity, itch, difficulty to sleep, anxiety and 
depression symptoms, and quality of life. Satisfaction with 
dupilumab compared to previous treatments was significantly 
higher in all aspects assessed. No significant dupilumab-induced 
laboratory abnormalities were noted, and adverse events were 
mild and transient. Conclusions: Dupilumab used under routine 
clinical practice for 52 weeks improved atopic dermatitis signs 
and symptoms, with a good safety profile and patient satisfaction.
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Objective: Atopic dermatitis affects patients’ quality of life 
(QoL) in many ways. It is important to analyze the impact that 
the disease produces in order to better define the healthcare needs 
of adult patients with atopic dermatitis. Patients and Methods: 
14 adult patients with atopic dermatitis were interviewed. The 
qualitative interviews were semi-structured and supported by a 
simple script, which allowed a complete and flexible interview. 
Results: Six affected areas of the patient’s life with atopic 
dermatitis were identified: economic, work-related, personal, 
psychosocial, clinical and relational. It is emphasized that 
atopic dermatitis has a great psychosocial impact on the adult 
patient, since it alters interpersonal relationships, generates 
rejection, stigmatization and social isolation, limits the patient 
in various areas and activities of their daily life or alters sleep, 
among others. The visible aspect, the itching-scratching cycle, 
the lack of awareness and ignorance of the disease, the lack of 
a definitive solution among the treatments and the side effects 
of some of them are of great concern. Conclusions: The QoL of 
the patients with atopic dermatitis is negatively affected and a 
holistic multidisciplinary intervention is necessary in order to 
mitigate the negative impact of the disease. 
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It has been reported the relation between depression and au-
toimmune blistering disease. Thus, The aim of the poster is: 
• To highlight the importance of the mental area in patients 
with autoimmune blistering disease, understanding it as a co-
